Lucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 Target

Ovid Therapeutics Inc. (NASDAQ:OVID) is among the best US stocks under $10 to invest in. Analysts at Lucid Capital have begun coverage on Ovid Therapeutics Inc. (NASDAQ:OVID) with a Buy rating and a price target of $5.50, reflecting a potential surge of nearly 467% from the current price.

Much of this optimism surrounds the company’s OV329, which is anticipated to achieve $1 billion in sales in the U.S. alone, five years after its launch. With a focus on treating epilepsy and seizure-related neurological disorders, Ovid Therapeutics Inc. (NASDAQ:OVID) establishes a strong foundation in the market that is expected to continue growing.

Additionally, Ovid Therapeutics Inc. (NASDAQ:OVID) is developing KCC2 activators that are critical chloride pumps enabling neurons to control excessive electrical activity. This means that through these activators, the company can target multiple diseases in an attempt to open the door to transformative therapies that have both clinical and market prospects.

Ovid Therapeutics Inc. (NASDAQ:OVID) is a New York-based biopharmaceutical company that provides solutions for people suffering from epilepsies and seizure-associated neurological disorders. Incorporated in 2014, the company is committed to improving each day for its patients.

While we acknowledge the potential of OVID as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.